JamesA.ReevesJr.MD

Oncology • Fort Myers, FL

Oncologist at Florida Cancer Specialists

Join to view full profile

Are you Dr. Reeves?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 117 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
8260 Gladiolus Dr
Fort Myers, FL 33908
Phone+1 239-437-5755

Fax+1 239-437-5776

Summary

Dr. James Reeves Jr., MD is an oncologist in Fort Myers, Florida. He is currently licensed to practice medicine in Florida, Louisiana, and Alabama. He is affiliated with Lee Memorial Hospital and Cape Coral Hospital.

Education & Training

University of Alabama Medical CenterFellowship, Hematology and Medical Oncology, 1985 - 1988
University of Alabama Medical CenterResidency, Internal Medicine, 1982 - 1985
Louisiana State University School of Medicine in New OrleansClass of 1982

Certifications & Licensure

FL State Medical License 1988 - 2025
AL State Medical License Active through 1988
LA State Medical License 1982 - 1984
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2014

Clinical Trials

A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma Start of enrollment: 2013 Feb 01
Terminated
Phase 2
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
Completed
Phase 2
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Start of enrollment: 2016 May 19
Active, not recruiting
Phase 2
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Start of enrollment: 2019 Jun 28
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer.
Alberto Bessudo, Abdul Mustajeeb Haseeb, James A Reeves, Xiaofu Zhu, Lucas Wong
Clinical Colorectal Cancer. 2024-09-01
Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary.
Harry E Fuentes Bayne, Pashtoon M Kasi, Li Ma, Lowell L Hart, Jenna Wong
JCO Precision Oncology. 2024-09-01
2 citations
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Gerald S Falchook, James Reeves, Sunil Gandhi, David R Spigel, Edward Arrowsmith
Cancer Immunology, Immunotherapy. 2024-03-02